STUTTGART, Germany I March 19, 2024 I La Merie Publishing released its newest product reviewing the pipeline of anti-CD38 approved and investigational antibodies, cell therapies and small molecules:
CD38-Targeted Antibody & Cell Therapy Pipeline Review
Targets: CD38; Cluster of Differentiation 38; ADP-ribosyl cyclase 1; ADPRC1
Product Category: Antibody; Cells; Small Molecule
This product provides basic information on approved and investigational antibodies, cell therapies and small molecules targeting CD38.
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
- Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for approved therapeis and therapy candidates targeting CD38 (prerequisite: access to internet).
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
CD38 is a transmembrane glycoprotein found on the surface of immune cells, including a range of bone marrow cells. In peripheral blood, CD38 is expressed on approximately 90% of plasma cells and approximately 60% of natural killer cells and monocytes. In normal cells, CD38 has many roles, in some instances stimulating lymphocytes, and in other circumstances inhibiting cell growth in B cell precursors. CD38 is an attractive target for antibody therapy because it is highly expressed on malignant plasma cells. In multiple myeloma, more than 90% of malignant plasma cells show surface expression of CD38. Expression is also seen in B cell and T cell neoplasms.
Multiple Myeloma (MM) is a hematological cancer characterized by proliferation of malignant plasma cells in the bone marrow. MM represents the second most frequent hematological malignancy, accounting 1% of all cancer and 13% of hematological tumors, with ~9,000 new cases per year. Multiple myeloma (MM) cells express high levels of the transmembrane glycoprotein CD38, while CD38 is expressed at relatively low levels on normal lymphoid and myeloid cells, and in some non-hematopoietic tissues. This expression profile, together with the role of CD38 in adhesion and as ectoenzyme, resulted in the development of CD38 antibodies for the treatment of multiple myeloma (MM). At this moment several CD38 antibodies are at different phases of clinical testing, with daratumumab and isatuximab already approved for various indications both as monotherapy and in combination with standards of care in MM.
Thus, CD38 is a clinically validated and commercially very successful target with a current market size of more than US$ 10 bln (in 2023) attracting interest for development of biosimilar and of biosuperior therapeutics.
The report “CD38-Targeted Antibody & Cell Therapy Pipeline Review” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/cd38-targeted-antibody-cell-therapy-pipeline-review/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE:La Merie Publishing
Post Views: 141
STUTTGART, Germany I March 19, 2024 I La Merie Publishing released its newest product reviewing the pipeline of anti-CD38 approved and investigational antibodies, cell therapies and small molecules:
CD38-Targeted Antibody & Cell Therapy Pipeline Review
Targets: CD38; Cluster of Differentiation 38; ADP-ribosyl cyclase 1; ADPRC1
Product Category: Antibody; Cells; Small Molecule
This product provides basic information on approved and investigational antibodies, cell therapies and small molecules targeting CD38.
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
- Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for approved therapeis and therapy candidates targeting CD38 (prerequisite: access to internet).
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
CD38 is a transmembrane glycoprotein found on the surface of immune cells, including a range of bone marrow cells. In peripheral blood, CD38 is expressed on approximately 90% of plasma cells and approximately 60% of natural killer cells and monocytes. In normal cells, CD38 has many roles, in some instances stimulating lymphocytes, and in other circumstances inhibiting cell growth in B cell precursors. CD38 is an attractive target for antibody therapy because it is highly expressed on malignant plasma cells. In multiple myeloma, more than 90% of malignant plasma cells show surface expression of CD38. Expression is also seen in B cell and T cell neoplasms.
Multiple Myeloma (MM) is a hematological cancer characterized by proliferation of malignant plasma cells in the bone marrow. MM represents the second most frequent hematological malignancy, accounting 1% of all cancer and 13% of hematological tumors, with ~9,000 new cases per year. Multiple myeloma (MM) cells express high levels of the transmembrane glycoprotein CD38, while CD38 is expressed at relatively low levels on normal lymphoid and myeloid cells, and in some non-hematopoietic tissues. This expression profile, together with the role of CD38 in adhesion and as ectoenzyme, resulted in the development of CD38 antibodies for the treatment of multiple myeloma (MM). At this moment several CD38 antibodies are at different phases of clinical testing, with daratumumab and isatuximab already approved for various indications both as monotherapy and in combination with standards of care in MM.
Thus, CD38 is a clinically validated and commercially very successful target with a current market size of more than US$ 10 bln (in 2023) attracting interest for development of biosimilar and of biosuperior therapeutics.
The report “CD38-Targeted Antibody & Cell Therapy Pipeline Review” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/cd38-targeted-antibody-cell-therapy-pipeline-review/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE:La Merie Publishing
Post Views: 141
